WO2011140973A1 - Visualization marker capable of making polymeric stent clearly visible under x-ray - Google Patents

Visualization marker capable of making polymeric stent clearly visible under x-ray Download PDF

Info

Publication number
WO2011140973A1
WO2011140973A1 PCT/CN2011/073894 CN2011073894W WO2011140973A1 WO 2011140973 A1 WO2011140973 A1 WO 2011140973A1 CN 2011073894 W CN2011073894 W CN 2011073894W WO 2011140973 A1 WO2011140973 A1 WO 2011140973A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
marker
mark
reserved hole
diameter
Prior art date
Application number
PCT/CN2011/073894
Other languages
French (fr)
Chinese (zh)
Inventor
谢建
魏征
Original Assignee
上海微特生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海微特生物技术有限公司 filed Critical 上海微特生物技术有限公司
Publication of WO2011140973A1 publication Critical patent/WO2011140973A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3966Radiopaque markers visible in an X-ray image
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028Shapes in the form of latin or greek characters
    • A61F2230/0052T-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063Three-dimensional shapes
    • A61F2230/0093Umbrella-shaped, e.g. mushroom-shaped
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0096Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
    • A61F2250/0098Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers

Definitions

  • the utility model relates to a development mark which can make a polymer stent clearly visible under X-rays, and belongs to the field of medical instruments. technical background
  • vascular stents Minimally invasive placement of vascular stents is widely used as an effective intervention technique for the treatment of vascular stenosis.
  • long-term retention of metal stents in blood vessels can cause chronic damage of blood vessels, which can cause atrophy of the middle layer of blood vessels and formation of aneurysms.
  • reactive intimal hyperplasia ultimately leading to the occurrence of vascular restenosis (Rab ST, KiHgsB, Roubin GS, et al. Coronary aneurysms after stent Placement: a suggestion of altered vessel wall healing in the Presence of anti-inflammatory agents. J Am Coll Cardiol 1991, 18:1524).
  • the stent Since the stent is implanted into the blood vessel, it mainly plays a role in mechanical support of the blood vessel within a certain time of injury healing (for a coronary stent generally within half a year), so the ideal vascular stent should be given sufficient mechanical support and healing in the lesion segment. It is then gradually absorbed by the body (Colombo A, Karvouni E. Biodegradable stents: "fulilling the mission and stepping away”. Circulation, 2000, 102: 371-373).
  • biodegradable polymer scaffold materials that can be completely absorbed by the human body are all polymer plastic materials.
  • the materials used for biodegradable vascular scaffolds are polylactic acid (PL), L-polylactic acid (PLLA or LP).
  • LA Polyglycolic acid/polylactic acid (PGLA), polycaprolactone (PCL), polyhydroxylbutyrate valerate (PHBV), polyacetylglutamic acid , PAGA), polyorthoesters (POE) and polyethylene oxide/polybutylene terephthalate (PEO/PBTP).
  • transparent plastic-based stents evade X-ray detection during medical procedures and patient visits, making development difficult. Therefore, the difficulty of safely and accurately placing the stent in the lesion site during surgery is greatly increased, and the surgical failure rate is increased. Moreover, postoperative observation is difficult and cannot provide direct treatment and reoperation for different patients. in accordance with.
  • Patent 200620158386. X describes a method for increasing the development of a stent by coating a developing film with gold and silver powder on both ends of the stent.
  • the adhesion of the coated developing film to the stent substrate may be due to the matrix material. Different and different.
  • a developing film having poor adhesion has a great risk of falling off during and after implantation, resulting in an acute thrombus.
  • a developing film having a different coating composition at both ends may cause an artificial coating unevenness, posing a risk to the treatment.
  • Patent 200920095643. 3 Describes a metal bracket using a two-layer material.
  • the double-layer material has a thick wall, is difficult to manufacture and subsequent processing, is expensive, and can only be applied to a bracket of a metal matrix material.
  • the utility model aims to find a channel which is safely applied to the development of a degradable polymer stent.
  • a development mark capable of making a polymer stent clearly visible under X-rays wherein a reserved hole (3) is disposed on the polymer support (2), and a mark body (1) is embedded in the reserved hole (3).
  • the mark (1) is a development mark (4) on the outer surface of the reserved hole (3), and the mark (1) does not protrude on the inner surface of the support at the other end of the reserved hole (3) .
  • This radiopaque marker can be applied to any polymer stent to improve the development of X-rays.
  • the radiopaque marker capable of developing the polymer stent is to be embedded in the polymer holder to be embedded in the reserved hole (3).
  • any part of the bracket can be selected as needed.
  • the connecting ribs at both ends of the bracket are generally selected as the set points of the reserved holes.
  • the shape of the reserved hole may be any suitable shape such as a circle, a plum shape, a star shape, a cross shape, a hexagon shape, or the like.
  • the size of the outer hole of the bracket is between 0. 18 ⁇ 0. 24mm, and the diameter of the inner surface of the bracket is not larger than the diameter of the outer surface of the reserved hole.
  • the diameter of the outer surface of the stent is 0. 01mm.
  • Gold or titanium, platinum, etc.
  • this kind of precious metal has good biocompatibility and has been widely used for filling teeth and manufacturing human implants.
  • a good material for radiopaque development marks Thanks to the good ductility of the material, the metal pellets can be easily pressed into the reserved holes of the polymer holder, and the wells are well matched with the reserved holes, and the marking points are firm.
  • the radiopaque marker capable of developing the polymer stent is to embed the marker body (1) from the outer surface of the polymer stent (2) into the bracket reserved hole (3), and to reserve the hole a developing mark (4) having a larger diameter than the outer surface of the reserved hole is formed on one side of the outer surface of the support, and the developing mark (4) is protruded from the outer surface 0. 01 0. 05 preferably 0. 03
  • the entire metal ball forms a metal "T" mark (5 ) Tightly fixed in the reserved hole, the other end of the "T” mark (5) does not protrude from the inner surface of the bracket (6).
  • This design ensures that the outer surface of the stent is tightly attached to the inner wall of the blood vessel after implantation, and the marker is tightly sandwiched between the stent and the blood vessel wall, and can withstand long-term vasoconstriction and blood flow impact without falling off.
  • the whole stent is wrapped in the blood vessel wall by the new tissue.
  • the degradable stent is completely absorbed, and the metal marker with excellent compatibility will be completely wrapped in the vessel wall. The blood flow is blocked.
  • the utility model can be used for X-ray development of any polymer-based stent, including but not limited to the above-mentioned polylactic acid (PLA), L-polylactic acid (PLLA or LPLA), Polyglycolic acid/polylactic acid (PGLA), polycaprolactone (PCL), polyhydroxylbutyrate valerate (PHBV), polyacetylglutamic acid (polyhydroxylbutyrate valerate, PHBV) Polyacetylglutamic acid, PLGA), polyorthoesters (POE) and polyethylene oxide/polybutylene terephthalate (PE0/PBTP).
  • PLA polylactic acid
  • PLLA or LPLA Polyglycolic acid/polylactic acid
  • PCL polycaprolactone
  • PHBV polyhydroxylbutyrate valerate
  • PHBV polyacetylglutamic acid
  • PLGA polyorthoesters
  • PE0/PBTP polyethylene oxide/polybutylene
  • Figure 1 is a plan view showing the outer surface of the bracket connecting rib after a circular reserved hole is provided.
  • Figure 2 is a side view of the metal ball placed on the reserved hole of the bracket before being buried.
  • Figure 3 is a side view of the marker position bracket after the metal pellet is buried in the reserved hole.
  • Figure 4 is a top plan view of the outer surface of the marker position after the metal pellet is buried in the reserved hole.
  • Fig. 5 is a schematic view showing the shape of a "rivet" formed after the metal ball is buried in the reserved hole.
  • Figure 6 is a cross-sectional side view of the marker position bracket after the metal ball is buried in the reserved hole.
  • Fig. 7 is a plan view showing the outer surface of the bracket connecting rib after setting a plum-shaped reserved hole.
  • Fig. 8 is a plan view showing the outer surface of the bracket connecting rib after the provision of a cross-shaped reserved hole.
  • Figure 9 is a top plan view of the outer surface of the bracket connecting rib after setting a star-shaped reserved hole.
  • Fig. 10 is a plan view showing the outer surface of the bracket connecting rib after the hexagonal reserved hole is provided. detailed description
  • the present invention provides a development mark that enables a polymer stent to be clearly visible under X-rays.
  • the recording body is a medical pure gold material, and the pure gold ball (1) is manually pressed into the reserved hole (3) of the polymer support by the outer surface of the polymer support (2), and a diameter larger than the reserved hole of the polymer is formed on the outer surface.
  • the pure gold ball pressed into the reserved hole forms a "T" mark (5) under the action of an external force, and is firmly fixed in the reserved hole (3) of the polymer.
  • the bracket material is PGLA, and the reserved holes are arranged on the connecting ribs at both ends of the bracket, which are round holes, and the reserved holes at both ends (3) are center-symmetrical, the size is 0.22 mm, and the diameter of the pure gold ball is 0.23 mm.
  • a development mark (4) larger than the outer surface diameter of the reserved hole is formed on the outer surface of the reserved hole holder, and the development mark (4) protrudes from the outer surface 0.03.
  • the metal ball forms a pure gold "T" mark (5) that is tightly fixed in the reserved hole, and the other end of the "T” mark (5) does not protrude from the inner surface of the bracket (6).

Abstract

A visualization marker capable of making a polymer stent clearly visible under X-ray is made of a marker body (1), and the material of the marker body (1) is gold, titanium, or platinum for medical use etc. The metallic marker body (1) is embedded in a prepared hole (3) of the stent from the outer surface of the polymer stent (2) in a manual manner, and at the side of the marker body (1) on the outer surface of the prepared hole (3) is formed a visualization marker (4) that is larger than the diameter of the outer surface of the prepared hole and protrudes from the outer surface of the stent, to form a "T" shaped marker(5) which is secured firmly in the prepared hole. The other side of the "T" shaped marker (5) does not protrude from the inner surface of the stent. After planting the stent, the marker is clamped firmly between the stent and the wall of blood vessel, so the marker can withstand long-term blood vessel movement and blood flow impaction but not fall off. The visualization marker has good visualization effect, and is safe for human body.

Description

一种能使聚合物支架在 X射线下清晰可见的显影标记 技术领域  Development marking for enabling polymer stents to be clearly visible under X-rays
本实用新型涉及一种能使聚合物支架在 X射线下清晰可见的显影标记, 属于医疗器械 领域。 技术背景  The utility model relates to a development mark which can make a polymer stent clearly visible under X-rays, and belongs to the field of medical instruments. technical background
血管支架微创置入作为一种行之有效的介入技术被广泛用于治疗血管狭窄, 但是, 金 属支架在血管内长期存留可引起血管的慢性损伤, 后期可造成血管中层的萎縮、 动脉瘤形 成及反应性的内膜增生, 最终导致血管再狭窄的发生(Rab ST, KiHgsB, Roubin GS, et al. Coronary aneurysms after stent Placement: a suggestion of altered vessel wall healing in the Presence of anti-inflammatory agents. J Am Coll Cardiol 1991, 18:1524 )。 由于支架植入血管后 主要是在损伤愈合的特定时间内对血管起力学支撑的作用(对于冠脉支架一般在半年内), 因此理想的血管支架, 应该给予病变段足够的机械支撑且在愈合后被机体逐步吸收 ( Colombo A, Karvouni E. Biodegradable stents:"fulilling the mission and stepping away". Circulation , 2000, 102:371-373 )。  Minimally invasive placement of vascular stents is widely used as an effective intervention technique for the treatment of vascular stenosis. However, long-term retention of metal stents in blood vessels can cause chronic damage of blood vessels, which can cause atrophy of the middle layer of blood vessels and formation of aneurysms. And reactive intimal hyperplasia, ultimately leading to the occurrence of vascular restenosis (Rab ST, KiHgsB, Roubin GS, et al. Coronary aneurysms after stent Placement: a suggestion of altered vessel wall healing in the Presence of anti-inflammatory agents. J Am Coll Cardiol 1991, 18:1524). Since the stent is implanted into the blood vessel, it mainly plays a role in mechanical support of the blood vessel within a certain time of injury healing (for a coronary stent generally within half a year), so the ideal vascular stent should be given sufficient mechanical support and healing in the lesion segment. It is then gradually absorbed by the body (Colombo A, Karvouni E. Biodegradable stents: "fulilling the mission and stepping away". Circulation, 2000, 102: 371-373).
近年来, 不少研究机构和血管支架生产商试图研制新型生物可降解性血管支架, 希望 这种支架既可暂时支撑血管壁, 保持血管通畅, 又能抑制早期血栓形成及晚期新生内膜增 生, 还可作为药物局部投放的载体, 达到有效防止支架置入后血管急性闭塞和降低再狭窄 发生率。  In recent years, many research institutes and vascular stent manufacturers have attempted to develop new biodegradable vascular stents. It is hoped that this stent can temporarily support the vessel wall, maintain vascular patency, and inhibit early thrombosis and advanced neointimal hyperplasia. It can also be used as a carrier for local drug delivery, effectively preventing the acute occlusion of the blood vessel after stent implantation and reducing the incidence of restenosis.
目前, 可完全被人体吸收的生物降解聚合物支架材料都是高分子塑料材料, 用于制作 生物降解血管支架的材料有聚乳酸 (polylacticacid, PLA)、 L-聚乳酸 (polyLlactic acid, PLLA或 LP LA) 聚羟基乙酸 /聚乳酸共聚物(polyglycolic acid/polylactic acid, PGLA)、 聚己内酯 (polycaprolactone, PCL)、 聚羟基丁酸戊酯 (polyhydroxylbutyrate valerate, PHBV)、 聚乙酰谷氨 酸(polyacetylglutamicacid, PAGA)、 聚正酯 (polyorthoesters, POE)和聚氧化乙烯 /聚丁烯共聚 物(polyethylene oxide/polybutylene terephthalate, PEO/PBTP)等。  At present, biodegradable polymer scaffold materials that can be completely absorbed by the human body are all polymer plastic materials. The materials used for biodegradable vascular scaffolds are polylactic acid (PL), L-polylactic acid (PLLA or LP). LA) Polyglycolic acid/polylactic acid (PGLA), polycaprolactone (PCL), polyhydroxylbutyrate valerate (PHBV), polyacetylglutamic acid , PAGA), polyorthoesters (POE) and polyethylene oxide/polybutylene terephthalate (PEO/PBTP).
与金属支架不同, 以透明塑料为基体的支架在医生手术和对病人回访检查中会逃避 X 射线的探测, 造成显影困难。 以至于大大增加了手术时在病灶部位安全准确放置支架的难 度, 增加手术失败率。 而且, 术后观察困难, 不能对不同病人术后治疗和再手术提供直接 依据。 Unlike metal stents, transparent plastic-based stents evade X-ray detection during medical procedures and patient visits, making development difficult. Therefore, the difficulty of safely and accurately placing the stent in the lesion site during surgery is greatly increased, and the surgical failure rate is increased. Moreover, postoperative observation is difficult and cannot provide direct treatment and reoperation for different patients. in accordance with.
目前已有不少研究对提高各类介入支架 X光下显影能力做过研究。  At present, many studies have done research on improving the imaging ability of various interventional stents under X-ray.
专利 200620158386. X 阐述了一种采用对支架两端涂覆带金银粉末的显影膜达到增加 支架显影效果的方法, 这种方法涂覆的显影膜与支架基体的粘合性会因为基体材质的不同 而参差不一。 粘合性能差的显影膜在植入过程中和植入后都会有极大的风险脱落, 导致产 生急性血栓。 而且对于本来要涂覆药物涂层的支架来说, 两端存在与药物涂层成分不一样 的显影膜会造成人为的涂层不均匀, 给治疗带来风险。  Patent 200620158386. X describes a method for increasing the development of a stent by coating a developing film with gold and silver powder on both ends of the stent. The adhesion of the coated developing film to the stent substrate may be due to the matrix material. Different and different. A developing film having poor adhesion has a great risk of falling off during and after implantation, resulting in an acute thrombus. Moreover, for a stent to which a drug coating is originally applied, a developing film having a different coating composition at both ends may cause an artificial coating unevenness, posing a risk to the treatment.
专利 200920095643. 3 阐述了一种采用双层材料的金属支架, 该类双层材料, 支架壁 厚大, 制造和后续加工困难, 价格昂贵而且只能适用于金属基体材料的支架。  Patent 200920095643. 3 Describes a metal bracket using a two-layer material. The double-layer material has a thick wall, is difficult to manufacture and subsequent processing, is expensive, and can only be applied to a bracket of a metal matrix material.
由此可见, 目前对于介入性支架的显影技术仍存在不少缺陷, 而且未见对可降解聚合 物支架显影技术的报道。  It can be seen that there are still many defects in the development technique of the interventional stent, and no reports on the development technology of the degradable polymer stent have been reported.
本实用新型旨在寻找一种渠道, 安全应用于可降解聚合物支架的显影用途。 实用新型内容  The utility model aims to find a channel which is safely applied to the development of a degradable polymer stent. Utility model content
本实用新型目的是提供一种可以安全应用于可降解聚合物支架的显影标记。  It is an object of the present invention to provide a development mark that can be safely applied to a degradable polymer scaffold.
本实用新型的这个以及其他目的将通过下列详细描述和说明来进一步体现和阐述。 一种能使聚合物支架在 X射线下清晰可见的显影标记, 是在聚合物支架 (2 ) 上设置 预留孔 (3), 在预留孔 (3 ) 内埋入标记体 (1 ), 形成 " T "形标记 (5), 标记体 (1 ) 在 预留孔 (3 ) 外表面是显影标记 (4), 标记体 (1 ) 在预留孔 (3 ) 另一端不突出支架内表 面。 这种不透射线标记可以适用于任何聚合物支架提高 X光下的显影效果。  This and other objects of the present invention will be further embodied and elucidated by the following detailed description and description. A development mark capable of making a polymer stent clearly visible under X-rays, wherein a reserved hole (3) is disposed on the polymer support (2), and a mark body (1) is embedded in the reserved hole (3). Forming a "T" mark (5), the mark (1) is a development mark (4) on the outer surface of the reserved hole (3), and the mark (1) does not protrude on the inner surface of the support at the other end of the reserved hole (3) . This radiopaque marker can be applied to any polymer stent to improve the development of X-rays.
所述的可以使聚合物支架显影的不透射线标记, 要在聚合物支架上预留标记埋入预留 孔 (3), 根据不同支架的长度和直径大小, 可以按需要选择支架的任何部位作为预留孔位 置点和预留孔的数量, 一般选取支架两端的连接筋作为预留孔的设置点。 预留孔的形状可 以是任何适用形状, 如圆形、 梅花形、 星形、 十字形、 六边形等。 其大小根据设置点筋宽 来设置, 一般预留孔在支架外表面的直径在 0. 18〜0. 24mm之间, 处于支架内表面的直径 不大于预留孔外表面直径。  The radiopaque marker capable of developing the polymer stent is to be embedded in the polymer holder to be embedded in the reserved hole (3). According to the length and diameter of the different brackets, any part of the bracket can be selected as needed. As the reserved hole position point and the number of reserved holes, the connecting ribs at both ends of the bracket are generally selected as the set points of the reserved holes. The shape of the reserved hole may be any suitable shape such as a circle, a plum shape, a star shape, a cross shape, a hexagon shape, or the like. The size of the outer hole of the bracket is between 0. 18~0. 24mm, and the diameter of the inner surface of the bracket is not larger than the diameter of the outer surface of the reserved hole.
所述的可以使聚合物支架显影的不透射线标记, 标记体黄金 (或钛、 铂金等) 材料的 纯度在 99. 9%以上, 未压入预留孔之前金属球直径在 0. 19〜0. 25mm之间, 大于预留孔在支 架外表面的直径 0. 01mm。 黄金 (或钛、 铂金等)具有最小的抗张力和良好的延展性, 抗氧 化性能好; 同时该类贵金属的生物相容性很好, 已广泛用于补牙和制造人体植入物, 是做 不透射线显影标记的良好材料。 得益于材料良好的延展性, 金属小球能容易被压进聚合物 支架预留孔中, 而且与预留孔配合良好, 标记点牢固。 〜1〜1〜1〜1〜1〜1〜1〜1 0毫米之间。 The diameter of the outer surface of the stent is 0. 01mm. Gold (or titanium, platinum, etc.) has minimal tensile strength and good ductility, and has good oxidation resistance. At the same time, this kind of precious metal has good biocompatibility and has been widely used for filling teeth and manufacturing human implants. A good material for radiopaque development marks. Thanks to the good ductility of the material, the metal pellets can be easily pressed into the reserved holes of the polymer holder, and the wells are well matched with the reserved holes, and the marking points are firm.
进一步地, 所述的可以使聚合物支架显影的不透射线标记, 在于将标记体 (1 ) 从聚 合物支架 (2 ) 外表面埋入支架预留孔 (3 ) 内, 并在预留孔支架外表面一侧形成大于预留 孔外表面直径的显影标记 (4), 显影标记 (4) 凸出外表面 0. 01 0. 05 优选 0. 03 整个金属球形成金属 " T "形标记 (5 ) 紧紧固定于预留孔内, " T "形标记 (5 ) 另一端 不突出支架内表面 (6)。 这种设计可保证支架在植入后外表面紧紧贴附与血管内壁, 将标 记紧紧夹在支架和血管壁之间, 能承受长时间血管收縮和血流冲击而不会脱落。 而血管内 皮化后, 支架整体被新生组织包裹在血管壁里, 随着时间推移, 可降解支架被完全吸收, 相容性极好的金属标记点将被完全包裹在血管壁内, 不会对血流产生阻塞。  Further, the radiopaque marker capable of developing the polymer stent is to embed the marker body (1) from the outer surface of the polymer stent (2) into the bracket reserved hole (3), and to reserve the hole a developing mark (4) having a larger diameter than the outer surface of the reserved hole is formed on one side of the outer surface of the support, and the developing mark (4) is protruded from the outer surface 0. 01 0. 05 preferably 0. 03 The entire metal ball forms a metal "T" mark (5 ) Tightly fixed in the reserved hole, the other end of the "T" mark (5) does not protrude from the inner surface of the bracket (6). This design ensures that the outer surface of the stent is tightly attached to the inner wall of the blood vessel after implantation, and the marker is tightly sandwiched between the stent and the blood vessel wall, and can withstand long-term vasoconstriction and blood flow impact without falling off. After endothelialization, the whole stent is wrapped in the blood vessel wall by the new tissue. Over time, the degradable stent is completely absorbed, and the metal marker with excellent compatibility will be completely wrapped in the vessel wall. The blood flow is blocked.
该实用新型可以用于任何以聚合物为基体的支架 X射线下显影之用, 包括但不仅限于 上述提及的聚乳酸 (polylacticacid, PLA)、 L-聚乳酸 (polyUactic acid, PLLA或 LPLA)、 聚羟基乙 酸 /聚乳酸共聚物 (polyglycolic acid/polylactic acid, PGLA)、 聚己内酉旨 (polycaprolactone, PCL)、 聚轻基丁酸戊酉旨(polyhydroxylbutyrate valerate, PHBV)、聚乙酰谷氨酸(polyacetylglutamicacid, PLGA )、 聚正酯(polyorthoesters, P0E)和聚氧化乙烯 /聚丁烯共聚物(polyethylene oxide/polybutylene terephthalate, PE0/PBTP)等。 附图说明  The utility model can be used for X-ray development of any polymer-based stent, including but not limited to the above-mentioned polylactic acid (PLA), L-polylactic acid (PLLA or LPLA), Polyglycolic acid/polylactic acid (PGLA), polycaprolactone (PCL), polyhydroxylbutyrate valerate (PHBV), polyacetylglutamic acid (polyhydroxylbutyrate valerate, PHBV) Polyacetylglutamic acid, PLGA), polyorthoesters (POE) and polyethylene oxide/polybutylene terephthalate (PE0/PBTP). DRAWINGS
图 1是设置一个圆形预留孔以后的支架连接筋外表面俯视图。  Figure 1 is a plan view showing the outer surface of the bracket connecting rib after a circular reserved hole is provided.
图 2是未埋入之前金属小球被放置在支架预留孔上侧视图。  Figure 2 is a side view of the metal ball placed on the reserved hole of the bracket before being buried.
图 3是金属小球埋入预留孔后标记位置支架侧视图。  Figure 3 is a side view of the marker position bracket after the metal pellet is buried in the reserved hole.
图 4是金属小球埋入预留孔后标记位置支架外表面俯视图。  Figure 4 is a top plan view of the outer surface of the marker position after the metal pellet is buried in the reserved hole.
图 5是金属小球埋入预留孔后形成的 "铆钉"形状示意图。  Fig. 5 is a schematic view showing the shape of a "rivet" formed after the metal ball is buried in the reserved hole.
图 6是金属小球埋入预留孔后标记位置支架剖面侧视图。  Figure 6 is a cross-sectional side view of the marker position bracket after the metal ball is buried in the reserved hole.
图 7是设置一个梅花形预留孔以后的支架连接筋外表面俯视图。  Fig. 7 is a plan view showing the outer surface of the bracket connecting rib after setting a plum-shaped reserved hole.
图 8是设置一个十字形预留孔以后的支架连接筋外表面俯视图。  Fig. 8 is a plan view showing the outer surface of the bracket connecting rib after the provision of a cross-shaped reserved hole.
图 9是设置一个星形预留孔以后的支架连接筋外表面俯视图。  Figure 9 is a top plan view of the outer surface of the bracket connecting rib after setting a star-shaped reserved hole.
图 10是设置一个六边形预留孔以后的支架连接筋外表面俯视图。 具体实施方式  Fig. 10 is a plan view showing the outer surface of the bracket connecting rib after the hexagonal reserved hole is provided. detailed description
参考图 1-6, 本实用新型的一种能使聚合物支架在 X射线下清晰可见的显影标记, 标 记体为医用纯金材料, 采用人工方式将纯金小球 (1) 由聚合物支架 (2) 外表面压入聚合 物支架预留孔 (3) 中, 并在外表面形成直径大于聚合物预留孔直径, 凸出外表面的显影 标记 (4) 形状的标记。 被压入预留孔的纯金球在外力作用下形成 "T"形标记 (5), 牢 固固定在聚合物预留孔 (3) 内。 支架材料为 PGLA, 预留孔设置在支架两端的连接筋上, 为圆孔, 两端预留孔 (3) 呈中心对称状, 大小为 0.22mm, 纯金小球直径 0.23mm。 将纯金 小球(1)压入预留孔 (3)后, 在预留孔支架外表面一侧形成大于预留孔外表面直径的显影标 记 (4), 显影标记 (4) 凸出外表面 0.03 整个金属球形成纯金 "T"形标记 (5) 紧紧 固定于预留孔内, "T"形标记 (5) 另一端不突出支架内表面 (6)。 Referring to Figures 1-6, the present invention provides a development mark that enables a polymer stent to be clearly visible under X-rays. The recording body is a medical pure gold material, and the pure gold ball (1) is manually pressed into the reserved hole (3) of the polymer support by the outer surface of the polymer support (2), and a diameter larger than the reserved hole of the polymer is formed on the outer surface. The diameter, the mark of the shape of the development mark (4) that protrudes from the outer surface. The pure gold ball pressed into the reserved hole forms a "T" mark (5) under the action of an external force, and is firmly fixed in the reserved hole (3) of the polymer. The bracket material is PGLA, and the reserved holes are arranged on the connecting ribs at both ends of the bracket, which are round holes, and the reserved holes at both ends (3) are center-symmetrical, the size is 0.22 mm, and the diameter of the pure gold ball is 0.23 mm. After the pure gold ball (1) is pressed into the reserved hole (3), a development mark (4) larger than the outer surface diameter of the reserved hole is formed on the outer surface of the reserved hole holder, and the development mark (4) protrudes from the outer surface 0.03. The metal ball forms a pure gold "T" mark (5) that is tightly fixed in the reserved hole, and the other end of the "T" mark (5) does not protrude from the inner surface of the bracket (6).

Claims

权利要求书 Claim
1、 一种能使聚合物支架在 X射线下清晰可见的显影标记, 其特征在于在聚合物支架 (2)上设置预留孔(3), 在预留孔(3 ) 内埋入金属标记体(1 ), 形成 " T "形标记( 5 ), 标记体 (1 ) 留在预留孔 (3 ) 外表面部分是显影标记 (4), 标记体 (1 ) 在预留孔 (3 ) 内 部分不突出支架内表面。 A development mark capable of making a polymer support clearly visible under X-rays, characterized in that a reserved hole (3) is provided on the polymer support (2), and a metal mark is embedded in the reserved hole (3) The body (1) forms a "T" mark (5), the mark body (1) remains in the reserved hole (3), the outer surface portion is a development mark (4), and the mark body (1) is at a reserved hole (3) The inner portion does not protrude from the inner surface of the bracket.
2、 根据权利要求 1所述的能使聚合物支架在 X射线下清晰可见的显影标记, 其特征 在于, 所述的支架预留孔 (3)设置于支架两端的连接筋上, 为圆孔或梅花孔或星形或十字形 或六边形。 2. The development mark according to claim 1, wherein the support hole (3) is disposed on the connecting rib at both ends of the support, and is a round hole. Or plum blossom holes or stars or crosses or hexagons.
3、 根据权利要求 1或 2所述的能使聚合物支架在 X射线下清晰可见的显影标记, 其 特征在于, 所述的支架预留孔 (3)的大小根据设置点筋宽来设置, 其直径在 0.18〜0.24mm, 处于支架内表面的直径不大于预留孔外表面直径。 3. The development mark according to claim 1 or 2, wherein the polymer support is clearly visible under X-rays, wherein the size of the support hole (3) is set according to a set point width. Its diameter is 0.18~0.24mm, and the diameter of the inner surface of the bracket is not larger than the diameter of the outer surface of the reserved hole.
4、 根据权利要求 1所述的能使聚合物支架在 X射线下清晰可见的显影标记, 其特征 在于所述标记体 (1)为直径在 0.19〜0.25mm, 比预留孔在支架外表面的直径大 0.01mm的小 球。 4. The development mark according to claim 1, wherein the mark body (1) has a diameter of 0.19 to 0.25 mm, and the reserved hole is on the outer surface of the holder. A small ball with a diameter of 0.01 mm.
5、 根据权利要求 1所述的能使聚合物支架在 X射线下清晰可见的显影标记, 其特征 在于, 所述的显影标记 (4)凸出外表面 0.01〜0.05mm, 优选 0.03mm, 其直径大于预留孔外 表面直径。 5. The development mark according to claim 1, wherein the development mark (4) protrudes from the outer surface by 0.01 to 0.05 mm, preferably 0.03 mm, and has a diameter. It is larger than the outer surface diameter of the reserved hole.
6、 根据权利要求 1所述的能使聚合物支架在 X射线下清晰可见的显影标记, 其特征 在于, 所述的标记体 (1)材料为医用黄金或钛或铂金。 6. The development mark according to claim 1, wherein the mark (1) material is medical gold or titanium or platinum.
PCT/CN2011/073894 2010-05-10 2011-05-10 Visualization marker capable of making polymeric stent clearly visible under x-ray WO2011140973A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201020184367.0 2010-05-10
CN2010201843670U CN202027751U (en) 2010-05-10 2010-05-10 Developing mark for enabling polymer support clearly seen in x-ray

Publications (1)

Publication Number Publication Date
WO2011140973A1 true WO2011140973A1 (en) 2011-11-17

Family

ID=44890067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/073894 WO2011140973A1 (en) 2010-05-10 2011-05-10 Visualization marker capable of making polymeric stent clearly visible under x-ray

Country Status (2)

Country Link
CN (1) CN202027751U (en)
WO (1) WO2011140973A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109984863A (en) * 2017-12-29 2019-07-09 先健科技(深圳)有限公司 The double-deck intravascular stent
CN109984864A (en) * 2017-12-29 2019-07-09 先健科技(深圳)有限公司 Bracket for branch vessel

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014064180A1 (en) * 2012-10-25 2014-05-01 Arterial Remodeling Technologies, Sa Radiopaque marker for bioresorbable stents
CN105457105B (en) * 2015-07-24 2018-08-31 中国科学院金属研究所 One kind can develop magnesium alloy blood vessel rack
CN107029306B (en) * 2016-02-04 2020-05-15 中国科学院金属研究所 Marker capable of developing degradation stent under X-ray and preparation method thereof
CN108464879B (en) * 2017-02-21 2020-04-10 上海微创医疗器械(集团)有限公司 Support frame
CN107596454B (en) * 2017-10-18 2024-03-08 苏州恒瑞迪生医疗科技有限公司 Absorbable endovascular prosthesis and preparation method thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334871B1 (en) * 1996-03-13 2002-01-01 Medtronic, Inc. Radiopaque stent markers
US6464720B2 (en) * 1997-09-24 2002-10-15 Cook Incorporated Radially expandable stent
US20040167619A1 (en) * 2003-02-26 2004-08-26 Cook Incorporated Prosthesis adapted for placement under external imaging
US20070156230A1 (en) * 2006-01-04 2007-07-05 Dugan Stephen R Stents with radiopaque markers
US20070266542A1 (en) * 2006-05-08 2007-11-22 Cook Incorporated Radiopaque marker for intraluminal medical device
US7625398B2 (en) * 2003-05-06 2009-12-01 Abbott Laboratories Endoprosthesis having foot extensions
CN101621974A (en) * 2007-02-09 2010-01-06 百乐仕医疗器械有限公司 Support

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334871B1 (en) * 1996-03-13 2002-01-01 Medtronic, Inc. Radiopaque stent markers
US6464720B2 (en) * 1997-09-24 2002-10-15 Cook Incorporated Radially expandable stent
US20040167619A1 (en) * 2003-02-26 2004-08-26 Cook Incorporated Prosthesis adapted for placement under external imaging
US7625398B2 (en) * 2003-05-06 2009-12-01 Abbott Laboratories Endoprosthesis having foot extensions
US20070156230A1 (en) * 2006-01-04 2007-07-05 Dugan Stephen R Stents with radiopaque markers
US20070266542A1 (en) * 2006-05-08 2007-11-22 Cook Incorporated Radiopaque marker for intraluminal medical device
CN101621974A (en) * 2007-02-09 2010-01-06 百乐仕医疗器械有限公司 Support

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109984863A (en) * 2017-12-29 2019-07-09 先健科技(深圳)有限公司 The double-deck intravascular stent
CN109984864A (en) * 2017-12-29 2019-07-09 先健科技(深圳)有限公司 Bracket for branch vessel
CN109984863B (en) * 2017-12-29 2020-04-07 先健科技(深圳)有限公司 Double-layer blood vessel support
CN109984864B (en) * 2017-12-29 2020-07-17 先健科技(深圳)有限公司 Stent for branch vessels
US10993821B2 (en) 2017-12-29 2021-05-04 Lifetech Scientific (Shenzhen) Co., Ltd Double-layer blood vessel stent

Also Published As

Publication number Publication date
CN202027751U (en) 2011-11-09

Similar Documents

Publication Publication Date Title
WO2011140973A1 (en) Visualization marker capable of making polymeric stent clearly visible under x-ray
US20220202997A1 (en) Dissolvable or degradable adhesive polymer to prevent stent migration
CA2493634C (en) Thermoplastic fluoropolymer-coated medical devices
CN105530895B (en) Work out support frame
JP4988570B2 (en) Bioabsorbable self-expanding intraluminal device
US9510934B2 (en) Implantable medical device having a sleeve
JP2009542352A (en) Stent with radiopaque marker and method for manufacturing the same
KR20160045802A (en) Surgical implant
JP2015155005A (en) Medical implant
US20210128329A1 (en) Tracheal stent
US11154643B2 (en) Platelet-activated bioadhesive stent coating as an anti-migration mechanism
Jackson et al. A viewpoint on material and design considerations for oesophageal stents with extended lifetime
CN216257635U (en) Self-expanding type covered stent
JP2023521091A (en) Self-expanding biodegradable stent braided with bioalloy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11780194

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 28.02.2013)

122 Ep: pct application non-entry in european phase

Ref document number: 11780194

Country of ref document: EP

Kind code of ref document: A1